# US 2023/0065964 A1 · Composition for enhancing urolithin production in a human subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065964 A1
- Document ID: US20230065964A1
- Status: Published application
- Kind: A1
- Application number: 17/911,920
- Filed: 2021-03-16
- Published: 2023-03-02
- Earliest claimed: 2020-03-16
- Applicants: Migalis ApS
- Inventors: Ina Giversen; Leif Helth Jensen
- Web page: https://patentgrep.com/patent/US20230065964A1

## CPC

- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a composition comprising 1) a preparation of Punica granatum L. and/or another source of ellagitannins and/or ellagic acid and 2) one or more human milk oligosaccharides (HMOs). Also disclosed herein is a method of increasing the production of urolithin A and/or other urolithins in the gut by administering said composition to a human subject.

## Claims

### Claim 1

A composition comprising:
a. a preparation of the fruit of Punica granatum, and
b. one or more human milk oligosaccharides (HMOs).

### Claim 2 (depends on 1)

A composition according to claim 1 wherein the HMO is a member selected from the group consisting of neutral HMOs or acidic HMOs.

### Claim 3 (depends on 1)

A composition according to claim 1 wherein the HMO is one or more fucosylated HMOs one or more non-fucosylated HMOs, or a mixture of fucosylated and non-fucosylated HMOs.

### Claim 4 (depends on 1)

A composition according to claim 1 wherein the one or more HMOs is a member selected from the group consisting of 2′-FL, 3-FL, DFL, LNT, LNnT, 3′-SL, 6′-SL, LNFP-1 or a mixture thereof.

### Claim 5 (depends on 1)

A composition according to claim 1 wherein the one or more HMOs comprises
a. 2′-FL and at least one of LNnT and LNT;
b. at least one of 2′-FL and DFL and at least one of LNnT and LNT;
c. 2′FL and 6′-SL;
d. DFL and 6′-SL;
e. 2′-FL, DFL and 6′-SL;
f 2′-FL, 6′-SL and at least one of LNnT and LNT; or
g. 2′-FL, DFL, 6′-SL and at least one of LNnT and LNT.

### Claim 6 (depends on 1)

A composition according to claim 1 which contains a preparation of the fruit of Punica granatum and one or more human milk oligosaccharides (HMOs) in a ratio (w/w) of from 5:1 to 1:10.

### Claim 7 (depends on 1)

A composition according to claim 1 formulated as a single preparation.

### Claim 8

A kit comprising
a. a preparation of the fruit of Punica granatum, and
b. one or more human milk oligosaccharides (HMOs),
as separate components, together with instructions for use.

### Claim 9 (depends on 1)

A method of treating a human subject identified as being a non-producer, which comprises orally administering to the subject a composition according to claim 1 in a daily dose of between 500-10000 mg HMOs/day and, 500-5000 mg of a preparation of the fruit of Punica granatum/day.

### Claim 10 (depends on 9)

The method of treatment according to claim 9 a, which comprises orally administering to the subject at least 75 mg punicalagins/day.

### Claim 11 (depends on 10)

The method according to claim 10 for use in the treatment of a human subject identified as being a urolithin non-producer which comprises orally administering to the subject at least 1000 mg HMOs/day.

### Claim 12 (depends on 1)

A method for increasing the production of urolithins in a human subject, in, said method comprising administering a composition according to claim 1.

### Claim 13 (depends on 12)

A method for increasing the production of urolithins in a human subject according to claim 12, which comprises administering to the subject at least 1000 mg HMOs/day.

### Claim 14 (depends on 1, 12)

A method for increasing the production of urolithins in a human subject according to claim 12, which comprises administering to the subject claim 1 at least 300 mg puncalagins/day.

### Claim 15 (depends on 12)

A method for increasing the production of urolithins in a human subject according to claim 12, wherein said urolithins comprise one or more of urolithin A, urolithin B and isourolithin A.
